Healthcare M&A » By The Online Investor Staff, updated Sun., Apr. 11, 9:47 PM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #19 of 100 |
Slide #19. Bristol-Myers Squibb — iPierian, Inc.
Acquirer:
Bristol-Myers Squibb (NYSE:BMY)
Acquiree:
iPierian, Inc.
Details:
Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold primarily to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics and government agencies. Co. manufactures products in the U.S. and Puerto Rico and has manufacturing operations in several foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Open the BMY Page at The Online Investor »
|
|||||||||||||||||||||
Open the BMY Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Buy (3.21 out of 4) 40th percentile
(ranked lower than approx. 60% of all stocks covered)
Analysts' Target Price: BMY Stock Forecast Based on Zacks ABR data; powered by Xignite |
